- Home
- COCP vs NERV Comparison
COCP vs NERV Comparison
Compare COCP & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | COCP | NERV |
|---|---|---|
| Founded | 2006 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.6M | 269.6M |
| IPO Year | 2011 | 2014 |
Fundamental Metrics
Financial Performance| Metric | COCP | NERV |
|---|---|---|
| Price | $1.03 | $6.18 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | $6.00 | ★ $7.00 |
| AVG Volume (30 Days) | 41.7K | ★ 320.5K |
| Earning Date | 05-14-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 8.02 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $12,712,091.00 | ★ $41,175,600.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.86 | $1.15 |
| 52 Week High | $2.19 | $12.46 |
Technical Indicators
Market Signals| Indicator | COCP | NERV |
|---|---|---|
| Relative Strength Index (RSI) | 49.97 | 45.30 |
| Support Level | $1.00 | $5.34 |
| Resistance Level | $1.11 | $6.69 |
| Average True Range (ATR) | 0.06 | 0.70 |
| MACD | -0.00 | -0.25 |
| Stochastic Oscillator | 29.63 | 18.24 |
Price Performance
Historical ComparisonAbout COCP Cocrystal Pharma Inc.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.